Featured Research

from universities, journals, and other organizations

Genetic regulator identified as possible treatment target in melanoma

Date:
April 3, 2014
Source:
Rutgers Cancer Institute of New Jersey
Summary:
The RUNX2 protein, which regulates the transcription of genetic messages responsible for the different functions of cells, may play a role in melanoma cell growth and spread, and could serve as a therapeutic target for the disease, research shows. Abnormal and uncontrolled production of this class of proteins, known as transcription factors, allow for cells to bypass growth control mechanisms and to develop characteristics necessary for invading surrounding tissues. Some transcription factors already have been identified as playing a role in melanoma development. These discoveries come into a favorable context of new drugs against transcription factors being tested in clinical trials.

Research from Rutgers Cancer Institute of New Jersey shows that the RUNX2 protein, which regulates the transcription of genetic messages responsible for the different functions of cells, may play a role in melanoma cell growth and spread and could serve as a therapeutic target for the disease.

Related Articles


Abnormal and uncontrolled production of this class of proteins, known as transcription factors, allow for cells to bypass growth control mechanisms and to develop characteristics necessary for invading surrounding tissues. Some transcription factors already have been identified as playing a role in melanoma development. These discoveries come into a favorable context of new drugs against transcription factors being tested in clinical trials. In the study, published in the current online edition of Cancer Letters, senior author Karine Cohen-Solal, PhD, and colleagues show for the first time that the RUNX2 transcription factor could also serve as a possible treatment target for melanoma.

This latest research shows deviant messaging translated through RUNX2 may result in melanoma growth, migration and invasion. In order to further understand the impact of such abnormal messaging, investigators artificially reduced the amount of RUNX2 in melanoma cells through a genetic approach. As a result, reduced abilities for cell growth, migration and invasion were found.

"Successful efforts to render transcription factors 'drugable' by interfering with different aspects of their transcriptional activity make this class of proteins attractive targets for therapy," says Dr. Cohen-Solal, a researcher at the Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. "Exploring the role of RUNX2 in the development of melanoma is likely to reveal new mechanisms driving melanoma progression and identify a target for novel anti-melanoma agents, thereby opening new avenues for the treatment of this disease."


Story Source:

The above story is based on materials provided by Rutgers Cancer Institute of New Jersey. Note: Materials may be edited for content and length.


Journal Reference:

  1. Rajeev K. Boregowda, Oyenike O. Olabisi, Walid Abushahba, Byeong-Seon Jeong, Keneshia K. Haenssen, Wenjin Chen, Marina Chekmareva, Ahmed Lasfar, David J. Foran, James S. Goydos, Karine A. Cohen-Solal. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Letters, 2014; DOI: 10.1016/j.canlet.2014.03.011

Cite This Page:

Rutgers Cancer Institute of New Jersey. "Genetic regulator identified as possible treatment target in melanoma." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403212358.htm>.
Rutgers Cancer Institute of New Jersey. (2014, April 3). Genetic regulator identified as possible treatment target in melanoma. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2014/04/140403212358.htm
Rutgers Cancer Institute of New Jersey. "Genetic regulator identified as possible treatment target in melanoma." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403212358.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins